Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study

Background: The bypassing agent, activated prothrombin complex concentrate [aPCC, FEIBA (factor VIII inhibitor bypass activity); Baxalta US Inc, a Takeda company, Lexington, MA, USA], is indicated for the treatment of bleeding episodes, perioperative management, and routine prophylaxis in patients w...

Full description

Bibliographic Details
Main Authors: Carmen Escuriola Ettingshausen, Cedric Hermans, Pål A. Holme, Ana R. Cid, Kate Khair, Johannes Oldenburg, Claude Négrier, Jaco Botha, Aurelia Lelli, Jerzy Windyga
Format: Article
Language:English
Published: SAGE Publishing 2023-07-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207231184323

Internet

https://doi.org/10.1177/20406207231184323

Similar Items